Continuous ambulatory peritoneal dialysis: Indian scenario.
Chronic peritoneal dialysis (CPD) has been initiated as a treatment modality for chronic renal failure patients in the Indian subcontinent since 1990. Over a period of 9 years both continuous ambulatory peritoneal dialysis (CAPD) and continuous cyclic peritoneal dialysis (CCPD) have emerged as accepted forms of renal replacement therapy in our country. Although there were government restrictions on import of dialysis fluid until 1993, the availability of locally manufactured fluid in collapsible bags had facilitated the expansion of the programme to the far corners of the country and in neighbouring countries. Initially majority (78%) of the patients who were started on this programme were diabetics with other comorbid conditions who were drop-outs from haemodialysis and unfit for transplantation. Both CAPD and CCPD have been used for all age groups and for men and women. Majority of the patients do 3 x 2 l exchanges a day on CAPD; 8-10 l using a cycler at night those who are onCCPD. Peritonitis rate was 1 episode every 18 patient months. With the introduction of new connection and disposable sets the incidence of peritonitis is dropping down. The major cause of drop-out is cardiovascular death followed by peritonitis. Malnutrition is a major problem in both CAPD and haemodialysis patients. The programme has been expanded and there are over one thousand patients on this treatment in the country. The introduction of CPD had a major impact on the treatment of renal failure in India.
Abraham
Georgi
G
Department of Nephrology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai.
Mathew
Milli
M
Hinduja
Anish
A
Padma
G
G
D001806:Blood Urea Nitrogen; D003928:Diabetic Nephropathies / Q000150:complications* / Q000175:diagnosis; D005260:Female; D006801:Humans; D007194:India; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000628:therapy*; D007677:Kidney Function Tests; D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects / Q000379:methods*; D011379:Prognosis; D018570:Risk Assessment; D016896:Treatment Outcome